Abattis Bioceuticals Corp (OTCMKTS:ATTBF) and Its Subsidiary Unveils a Marketing Campaign


Abattis Bioceuticals Corp (OTCMKTS:ATTBF) along with Vergence Naturals Ltd., its wholly owned subsidiary, have introduced a natural marketing campaign “Live. Love. Life. Naturally” to improve awareness about their naturally inspired beauty and health brands targeted at cannabinoid and conventional markets.

As part of this campaign, both the firms staged a decision to promote Vergence’s services and products. Chief Executive Officer and President of Abattis, Rob Abenante said the company is pleased with the progress achieved through Vergence, the distribution, and marketing arm.

The company has appointed Dr. Brazos Minshew to head medical advisory board. He will also function as President (Corporate Advisory Board) of Vergence. According to Abenante, the company is looking to develop innovative natural products and new formulations aimed at the cannabis enhanced and conventional markets.

Natural Life Enhancement Products of Vergence

The product line of Vergence to improve the quality of life of clients naturally include pharma and nutraceuticals, food and personal care, spa and beauty and beverages. All these products are manufactured using clean, raw and natural products to maximize the health benefits.

According to Vergence, all of its products are developed and manufactured after a thorough scientific research and safe to use.

Blockstrain Technology Corp (OTCMKTS:BKKSF) and Abattis Bioceuticals Corp Enters Into a Collaborative Accord For Product Integration

Blockstrain Technology Corp (OTCMKTS:BKKSF) and Abattis Bioceuticals Corp have entered into a strategic partnership. As per the LOI, Abattis will utilize the proprietary technology of Blockstrain in its products and services.

The clients of Abattis can now arrange for the sales as well as shipping and testing of the Abattis products and provide a clear visibility for all such products over the entire lifecycle.

Both the companies will utilize the integration and development opportunities for expanding the biotechnology and current life sciences offerings of Abattis.

Abattis can make use of the BLOCKStrain’s platform for storing all of the testing data in the distributed database. It helps to significantly lower the development costs and the workload. The manufacturers are also flexible to genetically test the strains and register with the Blockstrain for establishing ownership of the strains developed by them.

The proprietary technology of Blockstrain also improves the visibility of the testing results to the government regulators, producers, and the consumers.


About Author

Leave A Reply